Table.1.
Baseline characteristics of patients in overall and propensity-matched cohorts
| Variable | Overall cohort (n = 101) | Propensity score matched cohort (n = 56) | ||||
|---|---|---|---|---|---|---|
| Amikacin or CMS treatment (n = 48) | Other treatments (n = 53) | p value | Amikacin or CMS treatment (n = 28) | Other treatments (n = 28) | p value | |
| Demographic information | ||||||
| Age (years), m (IQR) | 74.5 (67–84.5) | 77 (67.5–82) | 0.796 | 77 (69.5–87) | 77 (66–82) | 0.640 |
| Male sex | 40 (83.3) | 40 (75.5) | 0.331 | 23 (79.3) | 21 (77.8) | 0.899 |
| Underlying condition | ||||||
| Charlson comorbidity index, m (IQR) | 4 (2–5.75) | 4 (2–6) | 0.961 | 3 (2–5) | 4 (2–6) | 0.337 |
| Diabetes mellitus | 13 (27.1) | 17 (32.1) | 0.583 | 8 (27.6) | 12 (44.4) | 0.188 |
| COPD | 15 (31.2) | 16 (30.2) | 0.908 | 5 (17.2) | 8 (29.6) | 0.273 |
| Cirrhosis | 2 (4.2) | 2 (3.8) | 1 | – | 1 (3.7) | 0.482 |
| Hematologic malignancy | 1 (2.1) | 16 (30.2) | < 0.001* | 1 (3.4) | 2 (7.4) | 0.605 |
| Solid tumor malignancy | 24 (50) | 25 (47.2) | 0.776 | 15 (51.7) | 11 (40.7) | 0.410 |
| Nephro-urological history | ||||||
| Baseline GFR (ml/min), m (IQR) | 58.1 (35–83) | 50 (25.5–83.5) | 0.835 | 43 (27–68.25) | 48 (27–82) | 0.476 |
| Chronic kidney disease | 10 (20.8) | 15 (28.3) | 0.385 | 8 (27.6) | 9 (33.3) | 0.640 |
| Dialysis | 1 (2.1) | 5 (9.4) | 0.208 | 1 (3.4) | 2 (7.4) | 0.605 |
| Renal transplant | 1 (2.1) | 4 (7.6) | 0.365 | – | 1 (3.7) | 0.482 |
| Benign prostatic hypertrophy | 14 (29.2) | 16 (30.2) | 0.911 | 7 (24.1) | 10 (37) | 0.386 |
| Obstructive urinary disease | 6 (12.5) | 6 (11.3) | 1 | 3 (10.3) | 1 (3.7) | 0.612 |
| Recurrent UTI | 20 (41.7) | 29 (54.7) | 0.19 | 15 (51.7) | 14 (51.9) | 0.992 |
| Indwelling urinary catheter in last 14 days | 36 (75) | 33 (62.3) | 0.202 | 23 (79.3) | 20 (74.1) | 0.643 |
| Other urological devices in last 14 days | 6 (12.5) | 12 (22.6) | 0.205 | 2 (6.9) | 1 (3.7) | 1 |
| Acquisition | ||||||
| Healthcare-related | 23 (51) | 28 (52.8) | 0.622 | 20 (69) | 13 (48.1) | 0.114 |
| Nosocomial | 25 (52.1) | 25 (47.2) | 0.622 | 9 (31) | 14 (51.9) | 0.114 |
| HCA risk factors | ||||||
| Hospital stay in last 3 months | 24 (50) | 33 (62.3) | 0.234 | 13 (48.1) | 17 (58.6) | 0.432 |
| Surgery in last 3 months | 22 (45.8) | 16 (30.2) | 0.150 | 12 (41.4) | 8 (29.6) | 0.359 |
| ICU admission in last 3 months | 13 (27.1) | 9 (17) | 0.238 | 7 (24.1) | 6 (22.2) | 0.865 |
| Residence in long-term care | 8 (16.7) | 6 (11.3) | 0.567 | 8 (27.6) | 1 (3.7) | 0.026* |
| Antibiotic exposure in last 3 months | 38 (79.2) | 49 (92.4) | 0.082 | 25 (86.2) | 24 (88.9) | 0.762 |
| Baseline illness severity | ||||||
| SOFA score, m (IQR) | 1 (0–2.7) | 2 (1–4) | 0.048* | 2 (0.5–3) | 2 (0–4) | 0.973 |
| Sepsis or septic shock | 11 (22.9) | 21 (39.6) | 0.072 | 10 (34.5) | 6 (22.2) | 0.310 |
| ICU admission | 5 (10.4) | 7 (13.2) | 0.764 | 5 (17.2) | 2 (7.4) | 0.424 |
| Bacteremia | 4 (8.3) | 17 (32.1) | 0.003* | 4 (13.8) | 4 (14.8) | 0.913 |
| Pitt score, m (IQR) | 2 (0.5–2.7) | 1 (0–1.5) | 0.282 | 2 (0.5–2.7) | 0.5 (0–1) | 0.134 |
| Management | ||||||
| Appropriate empirical treatment | 8 (16.7) | 13 (24.5) | 0.331 | 6 (20.7) | 5 (18.5) | 0.838 |
| Appropriate definitive treatment | 48 (100) | 49 (92.5) | 0.119 | 29 (100) | 24 (88.4) | 0.106 |
| 72 h delay to start appropriate antibiotic treatment | 24 (50) | 30 (56.6) | 0.506 | 15 (51.7) | 18 (66.7) | 0.256 |
| Adequate source control | 44 (91.7) | 46 (86.8) | 0.432 | 27 (93.1) | 24 (88.9) | 0.580 |
Data are presented as n (%), unless otherwise specified
CMS colistimethate sodium, COPD chronic obstructive pulmonary disease, GFR glomerular filtration rate, UTI urinary tract infection, HCA healthcare acquired, ICU intensive care unit, SOFA Sequential Organ Failure Assessment, m median, IQR interquartile range
*Statistical significance at p < 0.05